Visual morbidity in macroprolactinoma: A retrospective cohort study
Authors' conclusion
In our cohort of 150 patients with macroprolactinoma, 40 patients (26.7%) presented with visual field defects, of which 61.5% achieved complete visual recovery with treatment. Patients that achieved complete visual recovery presented with smaller macroadenomas, lower serum prolactin levels, lower rates of central hypogonadism and central hypothyroidism, lower rates of compressive optic neuropathy and better visual acuity.
Study context
- Population
- Patients with macroprolactinoma treated medically and surgically; median follow-up 6.0 years (IQR 2.9–10.6)
- Participants
- 150 patients
- Exposure
- Complete visual recovery vs no complete recovery
- Complete recoveryn = 24
- Outcome
- Complete visual field recovery
- Follow-up
- End
Main finding
As reported in the abstract
Complete recovery among available visual field tests
24 out of 39
61.5%
Observational data: associations, not effects.
Further findings
Macroadenoma size at diagnosis · smaller with complete recovery
P < 0.01
Baseline serum prolactin · lower with complete recovery
P < 0.01
Central hypogonadism
P = 0.05
Central hypothyroidism
P = 0.04
Compressive optic neuropathy
P = 0.02
Visual acuity better than 6/8 in both eyes
P < 0.01
Visual field defects at diagnosis
- Visual field defects
- 40 patients (26.7%)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →